


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

 Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use many sheets as necessary)		<b>Complete If Known</b>	
		Application Number	10/714,508
		Filing Date	11/14/2003
		First Named Inventor	Kevin Z. Qu
		Group Art Unit	1645
		Examiner Name	Unknown
Sheet 1 of 5		Attorney Docket Number	034827-3002

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
SKM	A1	5,359,045		Soubrier et al.	10-25-1994	
↓	A2	6,008,373		Waggoner et al.	12-18-1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
SKM	A3	Amant et al., "D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting." <i>Circulation</i> , 96:56-60 (1997)	
↓	A4	Beohar et al., "Angiotensin-I converting enzyme genotype DD is a risk factor for coronary artery disease." <i>J Investing Med</i> 43:275-280 (1995)	
	A5	Cambien et al., "Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction." <i>Nature</i> 359: 641-44 (1992).	
	A6	Cambien, "The antidiogenin-converting enzyme (ACE) genetic polymorphism: its relationship with plasma ACE level and myocardial infarction." <i>Clin Genetic</i> ; 46:94-101 (1992)	
↓	A7	Dakik et al. "Association of angiotensin I-converting enzyme gene polymorphism with myocardial ischemia and patency of infarct-related artery in patients with acute myocardial infarction." <i>J Am Coll Cardiol</i> , 29:1468-73 (1997)	

Examiner Signature	Stephanie K. Mummert	Date Considered	3/10/06
--------------------	----------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/714,508
		Filing Date	11/14/2003
		First Named Inventor	Kevin Z. Qu
		Group Art Unit	1645
		Examiner Name	Unknown
Sheet	2	of	5
		Attorney Docket Number	034827-3002

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>9</sup>
SKM	A8	de Azevedo et al., "ACE and PC-1 gene polymorphisms in normoalbuminuric Type 1 diabetic patients: A 10-year prospective study." J Diabetes and Its Compl;16:255-262 ,(2002)	
	A9	Dolnik, "DNA sequencing by capillary electrophoresis (review)." J Biochem. Biophys. Meth. 41:103-19, (1999)	
	A10	Dovichi and Zhang, DNA Sequencing by capillary array electrophoresis. Meth. Mol. Biol. 167:225-39, (2001)	
	A11	Gardemann et al., "ACE I/D gene polymorphism: presence of the ACE A allele increases the risk of coronary artery disease in younger individuals." Atherosclerosis, 139:153-159 (1998)	
	A12	Grifa et al., Screening of neurofibromatosis type 1 gene : identification of a large deletion and of an intronic variant. Clin. Genet. 47: 281-84 (1995)	
	A13	Hafner et al., Isothermal amplification and multimerization of DNA by Bst DNA polymerase. Biotechniques Apr;30(4):852-6, 858, 860 passim (2001).	
	A14	Heller, Principles of DNA separation with capillary electrophoresis Electrophoresis 22:629-43, (2001)	
✓	A15	Higaki et al., "Deletion allele of antiotensin-converting enzyme gene increases risk of essential hypertension in Japanese men: The Suita Study." Circulation 101: 2060-65 (2000)	

Examiner Signature	Stephanie K. Mummert	Date Considered	3/10/06
--------------------	----------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	10/714,508
		<b>Filing Date</b>	11/14/2003
		<b>First Named Inventor</b>	Kevin Z. Qu
		<b>Group Art Unit</b>	1645
		<b>Examiner Name</b>	Unknown
(use as many sheets as necessary)		<b>Attorney Docket Number</b>	034827-3002
Sheet	3	of	5

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
SKM	A16	Kampke et al., Efficient primer design algorithms," <i>Bioinformatics</i> 17: 214-225 (2001)	
	A17	Kennon et al., Angiotensin-converting enzyme gene and diabetes mellitus. <i>Diabet. Med.</i> 16: 448-58 (1999)	
	A18	Kurland et al., Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. <i>J. Hypertens.</i> 19: 1783-87 (2001)	
	A19	Marian et al., "Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin." <i>J Am Coll Cardiol</i> 35:89-95 (2000)	
	A20	McNamara et al., "Pharmacogenetic interactions between B-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart disease." <i>Circulation</i> 103:1644-1648 (2001)	
	A21	Mitchelson, The application of capillary electrophoresis for DNA polymorphism analysis <i>Methods Mol. Biol.</i> 162:3-26, (2001)	
	A22	Morris and Zee, Similarity of blood pressure for each genotype of the insertion/deletion polymorphism of the dipeptidyl carboxypeptidase-1 gene in different age groups of patients with severe, familial essential hypertension." <i>Clin. Exp. Pharmacol., Physiol.</i> 21: 919-24 (1994)	
✓	A23	O'Malley et al., "Angiotensin-converting enzyme DD genotype and cardiovascular disease in heterozygous familial hypercholesterolemia." <i>Circulation</i> 97:1780-1783 (1998)	

Examiner Signature	Stephanie K. Mummert	Date Considered	3/10/06
--------------------	----------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete If Known</b>	
		Application Number	10/714,508
		Filing Date	11/14/2003
		First Named Inventor	Kevin Z. Qu
		Group Art Unit	1645
		Examiner Name	Unknown
		Attorney Docket Number	034827-3002
Sheet	4	of	5

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
SKM	A24	Odawara et al., Mistyping frequency of the angiotensin-converting enzyme gene polymorphism and an improved method for its avoidance. Hum. Genet. 100: 163-66 (1997)	
	A25	Okamura et al., "Pharmacogenetic analysis of the effect of angiotensin-converting enzyme inhibitor on restenosis after percutaneous transluminal coronary angioplasty." Angiology, 50:811-822 (1999)	
	A26	Okumura et al., Quinapril prevents restenosis after coronary stenting in patients with angiotensin-converting enzyme D allele. Circ. J. 66: 311-316 (2002)	
	A27	Pfohl et al., "Insertion/deletion polymorphism of the antiotensin I-converting enzyme gene is associated with coronary artery plaque calcification as assessed by intravascular ultrasound." JACC 1998; 31:987-991	
	A28	Protonotarios et al., Genotype-phenotype assessment in autosomal recessive arrhythmogenic right ventricular cardiomyopathy (Naxos Disease) caused by a deletion in plakoglobin J. Am. Coll. Cardiol. 38: 1477-84 (2001)	
	A29	Ribichini et al., Plasma activity and insertion/Deletion polymorphism of angiotensin I-converting enzyme. Circulation 97: 147-54 (1998)	
	A30	Rigat et al., PCR detection of the Insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1) Nucl. Acid Res. 20: 1433 (1992)	
	A31	Ruiz et al., "Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus." Proc Natl Acad Sci USA 3662-3665 (1994)	

Examiner Signature	Stephanie K. Munnick	Date Considered	2/10/06
--------------------	----------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/714,508
		Filing Date	11/14/2003
		First Named Inventor	Kevin Z. Qu
		Group Art Unit	1645
		Examiner Name	Unknown
(use as many sheets as necessary)		Attorney Docket Number	034827-3002
Sheet	5	of	5

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
SPM ↓	A32	Saiki, "Amplification of Genomic DNA" in <i>PCR Protocols</i> , Innis et al., Eds., Academic Press, San Diego, CA 1990, pp 13-20;	
	A33	Shanmugan et al., Mistyping ACE heterozygotes. <i>PCR Methods Applications</i> 3: 120-21 (1993)	
	A34	van der Weide and Steijns, Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. <i>Ann. Clin. Biochem.</i> 36: 722-29 (1999)	
	A35	Wharam et al., Specific detection of DNA and RNA targets using a novel isothermal nucleic acid amplification assay based on the formation of a three-way junction structure. <i>Nucleic Acids Res.</i> Jun 1;29(11):E54-E54 (2001)	
	A36	Winkelmann et al., "Pharmacogenomics and Complex Cardiovascular Diseases - Clinical Studies in Candidate Genes," in <i>Pharmacogenomics</i> , Licinio and Wong, eds., pp. 251-61, Wiley-VCH, (2002)	
	A37	Zee et al., Insertion variant in intron 9, but not microsatellite in intron 2, of the insulin receptor gene is associated with essential hypertension. <i>J. Hypertens. Suppl.</i> 12: S13-S22 (1994)	

Examiner Signature	Stephanie K. Munn	Date Considered	3/10/06
--------------------	-------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.